Evogene (XTAE:EVGN) Accounts Payable & Accrued Expense : ₪16.50 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Evogene Accounts Payable & Accrued Expense?

Evogene's quarterly accounts payable & accrued expense increased from Sep. 2023 (₪15.83 Mil) to Dec. 2023 (₪19.87 Mil) but then declined from Dec. 2023 (₪19.87 Mil) to Mar. 2024 (₪16.50 Mil).

Evogene's annual accounts payable & accrued expense declined from Dec. 2021 (₪20.99 Mil) to Dec. 2022 (₪17.26 Mil) but then increased from Dec. 2022 (₪17.26 Mil) to Dec. 2023 (₪19.87 Mil).

Evogene Accounts Payable & Accrued Expense Historical Data

The historical data trend for Evogene's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene Accounts Payable & Accrued Expense Chart

Evogene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

16.47

17.24

20.99

17.26

19.87

Evogene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															15.67	16.98	15.83	19.87	16.50

Evogene Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Evogene (XTAE:EVGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (XTAE:EVGN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

EVGN:USA

Address

13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002

Website

https://www.evogene.com

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.